BrainCheck vs Creyos (2026)
Two digital cognitive assessment platforms with different claims to authority. BrainCheck's flagship is a regulated Class II device producing a structured cognitive result, paired with care planning so the score leads into a pathway rather than sitting on its own. Creyos comes from an academic lineage and its twelve task battery carries a large independent research base, applied broadly across cognitive and behavioural assessment and delivered as a link the patient completes anywhere. The distinction to hold is regulatory language: a clearance means a regulator reviewed performance, while a platform described as registered with the regulator has completed an administrative listing and nothing more. Neither publishes performance by education level, primary language or cultural background, which is the oldest known validity problem in cognitive testing and the one most likely to produce a wrong answer about a real patient.
- The flagship assessment is a regulated Class II device delivering a structured cognitive result, which is a higher bar than a validated questionnaire and matters when the output informs a dementia workup.
- Care planning sits alongside assessment, so the result leads somewhere rather than terminating in a score.
- For a primary care practice building a cognitive care pathway, the device status and the pathway support are both part of the purchase.
- The task battery has a large and genuinely independent research base behind it from its academic origins, which is unusual in this segment.
- Breadth is a real differentiator, with the same battery applied across cognitive and behavioural health assessment rather than one condition.
- Delivery is simple: a clinician sends a link and the patient completes the assessment in clinic or at home, with no device to deploy.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. BrainCheck and Creyos are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | BrainCheck | Creyos |
|---|---|---|
| Primary category | Clinical Decision Support | Clinical Decision Support |
| Founded | 2015 | 2009 |
| Headquarters | Austin, Texas, United States | Toronto, Ontario, Canada |
| Website | braincheck.com | creyos.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards BrainCheck its top capability grade on several axes, including Autonomy and Oversight Model, Clinical and Operational Evidence and HIPAA and BAA Posture. Set against Creyos, BrainCheck grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index records no top capability grade for Creyos on any axis it scores. Set against BrainCheck, Creyos does not grade higher on any scored axis, though the two are level on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Its thinnest published disclosure sits on several axes, including AI Centrality, Model Supply Chain Disclosure and HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose BrainCheck or Creyos?
The AI Health Index grades BrainCheck higher than Creyos on every axis that separates them, several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Creyos does not grade higher on any scored axis.
Where do BrainCheck and Creyos differ most?
The widest separation the AI Health Index records between BrainCheck and Creyos is on HIPAA and BAA Posture, where BrainCheck grades A and Creyos grades D. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do BrainCheck and Creyos grade the same?
The AI Health Index grades BrainCheck and Creyos the same on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have BrainCheck and Creyos not disclosed?
At the last review, at least one of BrainCheck and Creyos published thin or absent detail on several axes, including AI Centrality, Model Supply Chain Disclosure and HIPAA and BAA Posture. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Read the regulatory language carefully on both sides, because the words differ in meaning: a Class II device clearance is a review of the product's performance, while describing a platform as registered with the regulator refers to establishment listing, which is an administrative step and not a review of anything. Creyos publishes no security attestation, trust centre or pricing.
Neither vendor publishes performance by education, primary language or cultural background, which is the central validity question in cognitive testing, since these instruments are known to perform differently across those groups and a misclassification here starts a dementia workup or ends one prematurely.